"Roche Continents" fosters innovation in science and art
- Details
- Category: Roche

AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments
- Details
- Category: AstraZeneca

MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer
- Details
- Category: AstraZeneca

Pfizer and Synthon enter into U.S. commercialization agreement for potential generic treatment of multiple sclerosis
- Details
- Category: Pfizer

Bristol-Myers Squibb establishes collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
- Details
- Category: Bristol-Myers Squibb

AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases
- Details
- Category: AstraZeneca

Merck announces application period for start-ups
- Details
- Category: Merck Group

More Pharma News ...
- Bayer significantly improves earnings
- AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa
- European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab)
- AstraZeneca completes agreement with Tillotts Pharma for Entocort
- Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients
- IRESSA approved by US FDA for first-line treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer
- Pfizer's Centers for Therapeutic Innovation and Jeffrey Modell Foundation announce collaboration